Editorials
Chloroquine and hydroxychloroquine in covid-19
BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1432 (Published 08 April 2020) Cite this as: BMJ 2020;369:m1432Read our latest coverage of the coronavirus outbreak
Related articles
- News Published: 01 April 2020; BMJ 369 doi:10.1136/bmj.m1335
- Editorial Published: 24 April 2020; BMJ 369 doi:10.1136/bmj.m1643
- Editorial Published: 19 May 2020; BMJ 369 doi:10.1136/bmj.m2018
See more
- When I use a word . . . Commercial clinical trialsBMJ May 30, 2023, 381 p1223; DOI: https://doi.org/10.1136/bmj.p1223
- Systemic problems in maternity services are part of wider systemic problems in the NHS in EnglandBMJ May 30, 2023, 381 p1228; DOI: https://doi.org/10.1136/bmj.p1228
- Helen Salisbury: Rebranding our experts in family medicineBMJ May 30, 2023, 381 p1229; DOI: https://doi.org/10.1136/bmj.p1229
- Nigeria considers law that would prevent doctors from leaving for five years after trainingBMJ May 30, 2023, 381 p1234; DOI: https://doi.org/10.1136/bmj.p1234
- John Launer: Ask a good questionBMJ May 30, 2023, 381 p1212; DOI: https://doi.org/10.1136/bmj.p1212
Cited by...
- Results Availability and Timeliness of Registered COVID-19 Clinical Trials: A Cross-Sectional Study
- Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multi-national network cohort study
- Descriptive epidemiology of 16,780 hospitalized COVID-19 patients in the United States
- Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-naive patients with RA: a multicentre cross-sectional study
- Prognostic factors in spanish COVID-19 patients: A case series from barcelona
- Characteristics and Outcomes of Hospitalized Young Adults with Mild Covid-19
- Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a retrospective cohort study
- Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19
- Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study
- Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions
- Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
- Studies of Novel Coronavirus Disease 19 (COVID-19) Pandemic: A Global Analysis of Literature
- QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin
- Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis
- Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus
- Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter
- A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity
- Evaluation of diversity levels of the integrase gene sequences coming from HIV-1 virus, supporting the lack of target specificity of ivermectin versus the integrase-importin complex in SARS-CoV-2 infection
- Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2
- Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
- COVID-19, hydroxychloroquine and the eighth alternative
- The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2
- Less is more, now more than ever
- Lack of efficacy of hydroxychloroquine in covid-19
- Donald Trump: a political determinant of covid-19
- Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics